These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1129 related items for PubMed ID: 28476941

  • 1. Systemic Chemotherapy as Salvage Treatment for Locally Advanced Rectal Cancer Patients Who Fail to Respond to Standard Neoadjuvant Chemoradiotherapy.
    Sclafani F, Brown G, Cunningham D, Rao S, Tekkis P, Tait D, Morano F, Baratelli C, Kalaitzaki E, Rasheed S, Watkins D, Starling N, Wotherspoon A, Chau I.
    Oncologist; 2017 Jun; 22(6):728-736. PubMed ID: 28476941
    [Abstract] [Full Text] [Related]

  • 2. [Comparison of long-term efficacy between watch and wait strategy and total mesorectal excision in locally advanced rectal cancer patients with clinical complete response after neoadjuvant therapy].
    Wang XH, Zhou CJ, Zhang S, Wang QX, Xiao WW, Ding PR, Chen G, Pan ZZ, Zeng ZF, Gao YH.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar 25; 23(3):266-273. PubMed ID: 32192306
    [Abstract] [Full Text] [Related]

  • 3. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
    Ouyang GL, Meng WJ, Shu P, Deng XB, Wu B, Jiang D, Zhuang H, Shen YL, Zhou ZG, Wang ZQ, Wang X.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr 25; 22(4):349-356. PubMed ID: 31054549
    [Abstract] [Full Text] [Related]

  • 4. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management.
    Smith JJ, Chow OS, Gollub MJ, Nash GM, Temple LK, Weiser MR, Guillem JG, Paty PB, Avila K, Garcia-Aguilar J, Rectal Cancer Consortium.
    BMC Cancer; 2015 Oct 23; 15():767. PubMed ID: 26497495
    [Abstract] [Full Text] [Related]

  • 5. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, Hofheinz RD, Ghadimi M, Wolff HA, Lang-Welzenbach M, Raab HR, Wittekind C, Ströbel P, Staib L, Wilhelm M, Grabenbauer GG, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G, Sauer R, Liersch T, German Rectal Cancer Study Group.
    Lancet Oncol; 2015 Aug 23; 16(8):979-89. PubMed ID: 26189067
    [Abstract] [Full Text] [Related]

  • 6. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.
    Chua YJ, Barbachano Y, Cunningham D, Oates JR, Brown G, Wotherspoon A, Tait D, Massey A, Tebbutt NC, Chau I.
    Lancet Oncol; 2010 Mar 23; 11(3):241-8. PubMed ID: 20106720
    [Abstract] [Full Text] [Related]

  • 7. Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204.
    Landry JC, Feng Y, Prabhu RS, Cohen SJ, Staley CA, Whittington R, Sigurdson ER, Nimeiri H, Verma U, Benson AB.
    Oncologist; 2015 Jun 23; 20(6):615-6. PubMed ID: 25926352
    [Abstract] [Full Text] [Related]

  • 8. Does Adjuvant Chemotherapy for Locally Advanced Resectable Rectal Cancer treated with Neoadjuvant Chemoradiotherapy have an impact on survival? A Single Moroccan Institute Retrospective Study.
    Seddik Y, Brahmi SA, Afqir S.
    Gulf J Oncolog; 2019 May 23; 1(30):29-32. PubMed ID: 31242979
    [Abstract] [Full Text] [Related]

  • 9. Evolving role of neoadjuvant therapy in rectal cancer.
    Schrag D.
    Curr Treat Options Oncol; 2013 Sep 23; 14(3):350-64. PubMed ID: 23828092
    [Abstract] [Full Text] [Related]

  • 10. Clinical Analysis of the Efficacy and Safety of Different Neoadjuvant Strategies in the Treatment of Locally Advanced Rectal Cancer.
    Chen W, Wang W, Huang S, Zhou L, Wang G, Chen W.
    Cancer Invest; 2024 Aug 23; 42(7):661-670. PubMed ID: 39037150
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study.
    Borg C, Mantion G, Boudghène F, Mornex F, Ghiringhelli F, Adenis A, Azria D, Balosso J, Ben Abdelghani M, Bachet JB, Vendrely V, François Y, Conroy T, Rio E, Roullet B, Spaëth D, Quero L, Lakkis Z, Coudert M, Ionescu-Goga M, Tanang A, André T.
    Clin Colorectal Cancer; 2019 Sep 23; 18(3):200-208.e1. PubMed ID: 31311761
    [Abstract] [Full Text] [Related]

  • 12. Pathological response and safety of two neoadjuvant strategies with bevacizumab in MRI-defined locally advanced T3 resectable rectal cancer: a randomized, noncomparative phase II study.
    Borg C, André T, Mantion G, Boudghène F, Mornex F, Maingon P, Adenis A, Azria D, Piutti M, Morsli O, Bosset JF.
    Ann Oncol; 2014 Nov 23; 25(11):2205-2210. PubMed ID: 25122693
    [Abstract] [Full Text] [Related]

  • 13. Improved Metastasis- and Disease-Free Survival With Preoperative Sequential Short-Course Radiation Therapy and FOLFOX Chemotherapy for Rectal Cancer Compared With Neoadjuvant Long-Course Chemoradiotherapy: Results of a Matched Pair Analysis.
    Markovina S, Youssef F, Roy A, Aggarwal S, Khwaja S, DeWees T, Tan B, Hunt S, Myerson RJ, Chang DT, Parikh PJ, Olsen JR.
    Int J Radiat Oncol Biol Phys; 2017 Oct 01; 99(2):417-426. PubMed ID: 28871992
    [Abstract] [Full Text] [Related]

  • 14. Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer.
    Cercek A, Roxburgh CSD, Strombom P, Smith JJ, Temple LKF, Nash GM, Guillem JG, Paty PB, Yaeger R, Stadler ZK, Seier K, Gonen M, Segal NH, Reidy DL, Varghese A, Shia J, Vakiani E, Wu AJ, Crane CH, Gollub MJ, Garcia-Aguilar J, Saltz LB, Weiser MR.
    JAMA Oncol; 2018 Jun 14; 4(6):e180071. PubMed ID: 29566109
    [Abstract] [Full Text] [Related]

  • 15. Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk ("ugly") locally advanced rectal cancer: study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT).
    van den Berg K, Schaap DP, Voogt ELK, Buffart TE, Verheul HMW, de Groot JWB, Verhoef C, Melenhorst J, Roodhart JML, de Wilt JHW, van Westreenen HL, Aalbers AGJ, van 't Veer M, Marijnen CAM, Vincent J, Simkens LHJ, Peters NAJB, Berbée M, Werter IM, Snaebjornsson P, Peulen HMU, van Lijnschoten IG, Roef MJ, Nieuwenhuijzen GAP, Bloemen JG, Willems JMWE, Creemers GJM, Nederend J, Rutten HJT, Burger JWA.
    BMC Cancer; 2022 Sep 06; 22(1):957. PubMed ID: 36068495
    [Abstract] [Full Text] [Related]

  • 16. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
    Hong YS, Nam BH, Kim KP, Kim JE, Park SJ, Park YS, Park JO, Kim SY, Kim TY, Kim JH, Ahn JB, Lim SB, Yu CS, Kim JC, Yun SH, Kim JH, Park JH, Park HC, Jung KH, Kim TW.
    Lancet Oncol; 2014 Oct 06; 15(11):1245-53. PubMed ID: 25201358
    [Abstract] [Full Text] [Related]

  • 17. Oxaliplatin-containing Preoperative Therapy in Locally Advanced Rectal Cancer: Local Response, Toxicity and Long-term Outcome.
    Dueland S, Ree AH, Grøholt KK, Saelen MG, Folkvord S, Hole KH, Seierstad T, Larsen SG, Giercksky KE, Wiig JN, Boye K, Flatmark K.
    Clin Oncol (R Coll Radiol); 2016 Aug 06; 28(8):532-9. PubMed ID: 26888115
    [Abstract] [Full Text] [Related]

  • 18. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer.
    Chau I, Brown G, Cunningham D, Tait D, Wotherspoon A, Norman AR, Tebbutt N, Hill M, Ross PJ, Massey A, Oates J.
    J Clin Oncol; 2006 Feb 01; 24(4):668-74. PubMed ID: 16446339
    [Abstract] [Full Text] [Related]

  • 19. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
    Huang Y, Huang SH, Chi P, Wang XJ, Lin HM, Lu XR, Ye DX, Lin Y, Deng Y.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar 25; 23(3):281-288. PubMed ID: 32192308
    [Abstract] [Full Text] [Related]

  • 20. The effects of chemoradiotherapy on recurrence and survival in locally advanced rectal cancers with curative total mesorectal excision: a prospective, nonrandomized study.
    Akgun E, Ozkok S, Tekin M, Yoldas T, Caliskan C, Kose T, Karabulut B, Sezak M, Elmas N, Ozutemiz O.
    World J Surg Oncol; 2017 Nov 22; 15(1):205. PubMed ID: 29166925
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.